News
MiCheck® Prostate will be offered at CLIAx by 20/20 GeneSystems in the USA
Shared CLIA lab to help diagnostics start-ups, including Australian-based Minomic,more rapidly enter the U.S. market Rockville, MD, September 28, 2021 – 20/20 GeneSystems, Inc., (“20/20”), announced the launch of its Clinical Lab Innovation Axcellerator (CLIAx),...
Minomic’s video from MedTech Cybersecurity Innovation Summit
The 2021 Macquarie Park MedTech/Cybersecurity Innovation Summit, which was held on 29 April, brought together industry, Government and academia in the local MedTech sector. This event formed part of the Macquarie Park Innovation Summit Series 2021. A series of themed...
Minomic enters into collaboration with GloriousMed to introduce MiCheck® Prostate into China
Sydney, April 20, 2021: GloriousMed Biomedical Group Co., Ltd ("GloriousMed") and Minomic International Ltd ("Minomic") of Australia officially executed the agreement, which formally launched the commercialization of MiCheck® Prostate, a prostate cancer early...
CEO Dr Brad Walsh at the Pathology Technology Association Canberra Innovation Day 2021
On 24 March 2021 at Senate Alcove, Parliament House Canberra, Dr. Brad Walsh, CEO of Minomic International Ltd, opened the innovations panel discussion. He covered topics around the innovation environment in Australia and how the Government can assist in facilitating...
Pipeline MiCheck® Pancreatic Cancer Diagnostic — Positive Results
We are delighted to report positive results from our collaborative research evaluating Minomic’s GPC-1 antibody for the detection of pancreatic cancer (one of the deadliest cancers) in collaboration with BARD1 Life Sciences Ltd EXO-NET exosome capture technology....
Minomic takes part in the NSW Going Global Export Program
At Minomic, we are proud to be part of the NSW Going Global Export Program, a NSW Government funded export assistance package, designed to boost NSW exports and unlock international markets for sustainable businesses following the impacts of COVID-19, the bushfires...
Industry News: MTPConnect’s COVID-19 Impact Report
Explore the impact of the pandemic lockdown on medtech, biotech and pharma sectors in Australia by downloading MTPConnect’s COVID-19 Impact Report.
Hot Off the Press – Minomic’s MiCheck® Prospective Trial Papers Published
Minomic International Ltd (Minomic) is pleased to report publication of our back-to-back papers covering the recent MiCheck® prospective trial in the journal Urologic Oncology. The two papers, “A comparison of prostate health index, total PSA, %free PSA, and proPSA in...
Minomic and Sienna enter collaboration agreement to develop pancreatic cancer test
Pancreatic cancer is the most lethal cancer in humans, with a 5-year survival rate of less than 10%. There are no liquid biopsy assays for the early detection of pancreatic cancer. There is independent evidence that the protein GPC-1 on exosomes is strongly elevated...
Industry News: Australian Biotech 2030 Vision to emerge from AusBiotech CEO Policy Forum
An Australian Biotechnology 2030 Vision (the Vision) – a decadal framework for the industry – was discussed by Minister Hunt, and supported by Minister Andrews, at the AusBiotech CEO Policy Forum in Canberra last week. Find out more about AusBiotech 2030 Vision
Healthcare Leadership Series: Interview with Brad Walsh
Click here to watch the interview with Brad Walsh, CEO of Minomic International Ltd. The interview is about: - The perspectives on leadership - Best aspects of being involved in the health sector - Important traits a leader should have in the sector - The biggest...
Minomic Secures First Prize with MiCheck® at the 2018 Innovation & Entrepreneurship Competition for Overseas High-Level Talents in China
Dr Brad Walsh awarded first prize to boost Minomic’s efforts for MiCheck® China launch - offering a better solution for prostate cancer diagnosis 13 September 2018: [Sydney] Diagnostic company Minomic International Ltd today announced it had secured first prize at the...
Minomic secures key patent in the United States and China
Minomic has received a Notice of Allowance for the company’s patent covering its cell surface antigen for the diagnosis of prostate cancer Sydney, Australia, 5 September 2018: Minomic International Ltd (Minomic), an immuno-oncology company specializing in the...
